依达拉奉联合红花黄色素对急性脑梗死患者神经功能、血脂水平及血液流变学的影响

Effects of Edaravone Combined with Safflower Yellow Pigment on Neurological Function, Blood Lipid Level and Hemorheology in Patients with Acute Cerebral Infarction

目的:探讨依达拉奉联合红花黄色素对急性脑梗死(ACI)患者神经功能、血脂水平及血液流变学的影响。方法:选取2017年1月到2018年8月期间我院收治的ACI患者70例,采用数字表法将患者随机分为对照组(n=34)和研究组(n=36),对照组在常规治疗的基础上给予红花黄色素治疗,研究组在对照组基础上联合依达拉奉治疗,两组均治疗14d,比较两组治疗后的临床疗效,比较两组治疗前后的神经功能[美国国立卫生院卒中量表(NIHSS)评分、神经元特异性烯醇化酶(NSE)和S-100β水平]、血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)]及血液流变学(全血黏度低切、全血黏度中切、全血黏度高切、血浆黏度)情况,记录两组治疗期间发生的不良反应。结果:研究组治疗14 d后临床总有效率为91.67%(33/36),高于对照组患者的73.53%(25/34)(P<0.05)。两组患者治疗14 d后NIHSS评分、NSE和S-100β水平较治疗前降低,且研究组低于对照组(P<0.05)。两组患者治疗14 d后TG、TC、LDL-C均较治疗前降低,且研究组低于对照组(P<0.05),HDL-C则较治疗前升高,且研究组高于对照组(P<0.05)。两组患者治疗14 d后全血黏度低切、全血黏度中切、全血黏度高切、血浆黏度均较治疗前降低,且研究组低于对照组(P<0.05)。两组不良反应发生率比较无差异(P>0.05)。结论:依达拉奉联合红花黄色素治疗ACI患者安全有效,可显著改善患者神经功能、血脂水平及血液流变学情况,临床应用价值较高。

Objective:To investigate the effects of edaravone combined with safflower yellow pigment on neurological function,blood lipid level and hemorheology in patients with acute cerebral infarction(ACI).Methods:70 patients with ACI who were treated in our hospital from January 2017 to August 2018 were selected.They were randomly divided into control group(n=34)and study group(n=36)by digital table method.The control group was treated with safflower yellow pigment on the basis of routine treatment.The study group was treated with edaravone on the basis of the control group.The two groups were treated with 14 d.The clinical efficacy of the two groups after treatment was compared.The neurological function[NIHSS score,neuron-specific enolase(NSE)and S-100βlevels],blood lipid level[triglyceride(TG),total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)]and hemorheology(whole blood viscosity low cut,whole blood viscosity in cut,whole blood viscosity high cut,plasma viscosity)were compared between the two groups before treatment and after treatment,and the adverse reactions were recorded.Results:The total effective rate was 91.67%(33/36)in the study group at 14 d after treatment,which was significantly higher than 73.53%(25/34)in the control group(P<0.05).The NIHSS score,NSE and S-100βlevels in both groups were lower at 14 days after treatment than before treatment,and the study group was lower than the control group(P<0.05).The levels of TG,TC and LDL-C in the two groups at 14 d after treatment were lower than before treatment,and the study group was lower than the control group(P<0.05),while the HDL-C was higher than that before treatment,and the study group was higher than that in the control group(P<0.05).The whole blood viscosity low cut,whole blood viscosity in cut,whole blood viscosity high cut,plasma viscosity were lower in the two groups at 14 d after treatment were lower than before treatment,and the study group was lower than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Edaravone combined with safflower yellow pigment is effective and safe in the treatment of patients with ACI.It can effectively improve the neurological function,blood lipid level and hemorheology of patients with ACI,the clinical application value is higher.